TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05411081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scans

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05275868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGY825
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGY825
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGY825
Description: investigational drug
Study: NCT05276063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linsitinib
Description: Study medication taken twice daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linsitinib
Description: Study medication taken twice daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice daily by mouth
Study: NCT06161688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensitrelvir
Description: Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Ensitrelvir
Study: NCT05565950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study: NCT05691738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
Study: NCT05695131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlenXRose Virtual Reality Speech Therapies
Description: Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
Study: NCT05502861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generalist + Specialist palliative care
Description: Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Intervention phase
Description: Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
Study: NCT06147778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuCopilot mobile application
Description: MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
Study: NCT05292924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early SCC
Description: Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
Study: NCT04840485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 low-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06269627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate calcium
Description: Two oral capsules (packaged as one) containing 666 mg of acamprosate calcium will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two oral capsules (packaged as one) containing 666 mg of inactive substance (e.g., sugar) will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
Study: NCT04803305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06946860
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-06946860
Description: subcutaneous injection
Study: NCT04297033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: lovastatin 40mg/d 12m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05458882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: living with food allergy educational booklet
Description: An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
Study: NCT06157632

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thyriodectomy
Description: Thyroidectomy
Study: NCT06582875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Titrated to dose of 5 mg once weekly subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titrated to dose of 5 mg once weekly subcutaneous
Study: NCT06582706

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: a readily available inert placebo will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Niacin
Description: 500 mg
Study: NCT05194111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
Study: NCT05944874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition transcranial direct current stimulation
Description: Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
Study: NCT05343351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technique of injection method
Description: In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technique of injection method
Description: In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel.
Study: NCT05380089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing water intake
Description: Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
Study: NCT06108635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie Exercises
Description: These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McKenzie Exercises
Description: These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland mobilization
Description: The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy
Description: Moist heat therapy with hot pack.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Moist heat therapy with hot pack.
Study: NCT05470088

Intervention type: OTHER
Intervention: Neuroimaging (MRI)
Description: Multimodal magnetic resonance imaging

Intervention type: OTHER
Intervention: Neuroimaging (MRI)
Description: Multimodal magnetic resonance imaging

Intervention type: OTHER
Intervention: Neuroimaging (MRI)
Description: Multimodal magnetic resonance imaging
Study: NCT06562907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4571
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4571
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4571
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4571
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study: NCT05876299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 95.1% Lean Pork
Description: This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 81.16% Lean Pork
Description: This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
Study: NCT06016400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol Oral Solution
Description: Alfacalcidol Oral Solution 1ug a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05876299

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Beverage
Description: This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
Study: NCT05127967

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
Study: NCT05610787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCOR Active Driving System for Pediatric VAD
Description: The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
Study: NCT05157113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dropless Regimen
Description: Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Regimen
Description: Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop.
Study: NCT05194111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
Study: NCT06581874

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clinical assessment by emergency psychiatrist
Description: After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation booked through Med@Psy platform
Description: The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
Study: NCT06583135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education and motivational interviewing
Description: The intervention group, will receive face-to-face sleep hygiene training and then 4 online motivational interviews will be held within 6 weeks. The online motivational interviews will be implemented in the 1st week (interview 1), 2nd week (interview 2), 4th week (interview 3), and 6th week (interview 4).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face sleep hygiene training
Description: The control group receive face-to-face sleep hygiene training
Study: NCT06238531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gusacitinib
Description: An orally active dual SYK/JAK kinase inhibitor
Study: NCT06303544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wedge 1
Description: Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
Study: NCT06153290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham adjustment
Description: A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
Study: NCT05098405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)
Description: The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Description: The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Study: NCT06412991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycle Therapy
Description: The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.